公开(公告)号：EP4461819A1

公开(公告)日：2024-11-13

申请号：EP22919080.6

申请日：2022-12-23

申请人： Seegene, Inc.

发明人： KWON, Suk-Tae ,  NA, Hyewon ,  CHO, Sung Suk ,  KWON, Chanho

IPC分类号： C12Q1/6848 ,  C12N9/24 ,  C12N15/52 ,  C12N15/70 ,  C07K1/16

摘要： The present invention relates to uracil-DNA glycosylase (UDG) derived from Photobacterium leiognathi and to the use thereof. The novel UDG of the present invention is an enzyme isolated from Photobacterium leiognathi, which is a psychrophilic bacterium, and is characterized by having an activity of degrading uracil bases from uracil-containing DNA substrate and being easily denatured at low temperatures. Accordingly, the UDG of the present invention can be effectively used to eliminate carryover contamination occurring during the nucleic acid amplification reaction, resulting in increased accuracy (elimination of false positives), purity and amplification efficiency in nucleic acid amplification reactions.

公开(公告)号：EP4461749A1

公开(公告)日：2024-11-13

申请号：EP23737076.2

申请日：2023-01-05

申请人： Shanghai Mabgen Biotech Ltd.

发明人： SHEN, Lijun ,  ZHAO, Zhilong ,  LI, Lei ,  TANG, Chenxiang

IPC分类号： C07K16/36 ,  A61K39/395 ,  A61K39/00 ,  C12N15/13

摘要： A pharmaceutical composition comprising an anti-FXI/FXIa antibody and the use thereof. The specific pharmaceutical composition to which the present disclosure relates comprises an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, and a buffer.

公开(公告)号：EP4461742A2

公开(公告)日：2024-11-13

申请号：EP24188657.1

申请日：2012-01-17

申请人： Bioniz Therapeutics, Inc.

发明人： TAGAYA, Yutaka ,  AZIMI, Nazli

IPC分类号： C07K14/55

摘要： The various embodiments relate to peptide antagonists of yc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21). The yc-cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of yc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual yc-cytokine family member/ receptor subunit. However, success has been limited and often multiple yc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus yc-subunit binding site to inhibit yc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple yc-cytokine family members.

公开(公告)号：EP4461737A1

公开(公告)日：2024-11-13

申请号：EP22916735.8

申请日：2022-12-28

申请人： JW Shinyak Corporation

发明人： JEON, Yoon Jae ,  KIM, Younghoon ,  HONG, Seungho

IPC分类号： C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  A61K47/42 ,  A61P35/00

摘要： The present invention relates to a polypeptide for delivering an antigen to immune cells and, specifically, to: a novel polypeptide comprising a cell membrane penetrating peptide and a peptide binding to a surface molecule on immune cells; a fusion polypeptide in which an antigen is coupled to the polypeptide; a nucleic acid coding for the polypeptide or the fusion polypeptide; an immune cell sensitized with the fusion polypeptide or the nucleic acid coding therefor; and an immunotherapeutic agent, antitumor or anticancer vaccine, and a composition for treating a tumor or cancer, each comprising the immune cell.

公开(公告)号：EP4461366A1

公开(公告)日：2024-11-13

申请号：EP22918494.0

申请日：2022-12-29

申请人： Suzhou Institute Of Systems Medicine

发明人： LI, Guideng ,  CHENG, Hongcheng ,  QIU, Yajing ,  XU, Yue

IPC分类号： A61P35/00 ,  C12N5/10 ,  C07K19/00 ,  A61K35/17 ,  A61K39/00

摘要： Construction of a T cell receptor and the use thereof are provided. Utilizing mutations of intracellular constant region sites of an α chain and an β chain of the T cell receptor to inhibit the degradation of the T cell receptor after TCR antigen signal activation, maintain the level of TCR on cell surface, and improve the efficacy of TCR-T cell therapy. This method can be applied to different TCR-T cell therapies.

公开(公告)号：EP4460698A1

公开(公告)日：2024-11-13

申请号：EP23737232.1

申请日：2023-01-04

申请人： Queensland University Of Technology

发明人： ALEXANDROV, Kirill ,  GUO, Zhong

IPC分类号： G01N33/94 ,  C07K14/47 ,  C07K16/18 ,  C07K16/44 ,  C12N9/04 ,  C12N9/24 ,  C12N9/86 ,  C12Q1/32 ,  C12Q1/34 ,  G01N33/542 ,  G01N33/68

公开(公告)号：EP4460525A2

公开(公告)日：2024-11-13

申请号：EP23737769.2

申请日：2023-01-06

申请人： Viridian Therapeutics, Inc.

发明人： BEDIAN, Vahe ,  ZHAO, Yang

IPC分类号： C07K16/28 ,  A61K39/39 ,  A61P5/14 ,  C07K7/00

公开(公告)号：EP4460524A2

公开(公告)日：2024-11-13

申请号：EP23737768.4

申请日：2023-01-06

申请人： Viridian Therapeutics, Inc.

发明人： BEDIAN, Vahe ,  ZHAO, Yang

IPC分类号： C07K16/28 ,  C07K16/22 ,  A61K39/39 ,  A61P35/00 ,  A61P17/00

公开(公告)号：EP4460523A2

公开(公告)日：2024-11-13

申请号：EP23737702.3

申请日：2023-01-04

申请人： Avalo Therapeutics, Inc.

发明人： NEIL, Garry A. ,  WILKINS, H. Jeffrey ,  CARRINGTON, Sheridan J.

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P11/06

公开(公告)号：EP4460521A1

公开(公告)日：2024-11-13

申请号：EP23704000.1

申请日：2023-01-04

申请人： Inhibrx Biosciences, Inc.

发明人： BECKLUND, Bryan R. ,  JONES, Kyle S. ,  ROBINSON, Kaitlyn N. ,  ECKLES, Andrew M. ,  TIMMER, John C. ,  ECKELMAN, Brendan P.

IPC分类号： C07K16/28